In vitro maturation as a fertility preservation strategy in cancer patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To describe a case series on the use of in vitro maturation (IVM) technology in patients with cancer.

Materials and methods: This study included 34 patients aged 23–43 years who presented to the IVF Department of the Medsi on Solyanka Clinical and Diagnostic Center for fertility preservation programs. Transvaginal puncture of the antral follicles was performed, followed by aspiration of the follicular fluid. The resulting oocyte-cumulus complexes (OCCs) were matured for 24–48 h in an embryology laboratory.

Results: IVM were performed in 34 patients. In one case, no oocytes were retrieved, and in five cases, mature oocytes were not obtained after the culture. A total of 185 OCCs were retrieved, averaging 5.4 OCCs per patient. Additionally, 95 mature oocytes at the MII stage were retrieved, averaging 2.9 per patient, resulting in an average maturation rate of 51.8%. Oocyte cryopreservation was conducted in 13 patients, resulting in a total of 47 oocytes, or an average of 3.6 oocytes per patient. Fertilization was performed using oocytes obtained after IVM in 15 patients. In 10 cases, embryos were not produced (due to lack of cleavage or embryos being unsuitable for transfer according to the PGT-A results). In five cases, embryos suitable for transfer to the uterine cavity were obtained (either euploid according to PGT-A or PGT-A was not performed). Embryo storage continued in two cases, while one patient discontinued embryo storage. Two thawed embryos were transferred: one into the patient's uterine cavity, which did not result in pregnancy, and the other into a surrogate mother's uterus, resulting in pregnancy and delivery.

Conclusion: IVM is a promising approach for fertility preservation in patients with cancer in whom ovarian stimulation is not feasible. The effectiveness of this technique is influenced by the patient's baseline parameters, primarily age and ovarian reserve. However, further research is required to standardize the approaches and enhance the efficacy of this technology.

Full Text

Restricted Access

About the authors

Anastasiya G. Syrkasheva

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Medsi on Solyanka Clinical and Diagnostic Center

Author for correspondence.
Email: anast.syrkasheva@gmail.com
ORCID iD: 0000-0002-7150-2230

Dr. Med. Sci., Associate Professor, Department of Obstetrics and Gynecology, Institute of Surgery, Pirogov Russian National Research Medical University, Ministry of Health of Russia; Head of the Department of Assisted Reproductive Technologies, CDC «Medsi on Solyanka»

Russian Federation, Moscow; Moscow

Yulia E. Dobrokhotova

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: pr.dobrohotova@mail.ru
ORCID iD: 0000-0002-9091-4097

Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology

Russian Federation, Moscow

Yael A. Gokhberg

Medsi on Solyanka Clinical and Diagnostic Center

Email: gohberg.ya@medsigroup.ru
ORCID iD: 0000-0003-3637-6096

PhD, obstetrician-gynecologist, Department of Assisted Reproductive Technologies

Russian Federation, Moscow

Maria N. Troshina

Medsi on Solyanka Clinical and Diagnostic Center

Email: troshina.mn@medsigroup.ru

Head of the Embryological Laboratory of the Department of Assisted Reproductive Technologies

Russian Federation, Moscow

Yuri A. Sorokin

Medsi on Solyanka Clinical and Diagnostic Center

Email: Sorokin.Yua@medsigroup.ru
ORCID iD: 0000-0001-9305-323X

Head of the Center for Reproductive Health

Russian Federation, Moscow

Irina A. Lapina

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Medsi on Solyanka Clinical and Diagnostic Center

Email: lapina.ia@medsigroup.ru
ORCID iD: 0000-0002-2875-6307

Dr. Med. Sci., Professor, Department of Obstetrics and Gynecology, Institute of Surgery, Pirogov Russian National Research Medical University, Ministry of Health of Russia; obstetrician-gynecologist, CDC «Medsi on Solyanka»

Russian Federation, Moscow; Moscow

References

  1. Filho A.M., Laversanne M., Ferlay J., Colombet M., Piñeros M., Znaor A. et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide. Int. J. Cancer. 2025; 156(7): 1336-46. https://dx.doi.org/10.1002/ijc.35278
  2. Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer. 2021. https://dx.doi.org/10.1002/ijc.33588
  3. Rives N., Courbière B., Almont T., Kassab D., Berger C., Grynberg M. et al. What should be done in terms of fertility preservation for patients with cancer? The French 2021 guidelines. Eur. J. Cancer. 2022; 173: 146-66. https://dx.doi.org/10.1016/j.ejca.2022.05.013
  4. Михайлова Н.Д., Мишиева Н.Г., Кириллова А.О., Мартазанова Б.А., Джинчарадзе Л.Г. Дозревание ооцитов in vitro. Акушерство и гинекология. 2021; 11: 64-70. [Mikhailova N.D., Mishieva N.G., Kirillova A.O., Martazanova B.A., Jincharadze L.G. Maturation of oocytes in vitro. Obstetrics and Gynecology. 2021; (11): 64-70 (in Russian)]. https://dx.doi.org/10.18565/aig.2021.11.64-70
  5. Anderson R.A., Amant F., Braat D., D'Angelo A., Chuva de Sousa Lopes S.M., Demeestere I. et al.; ESHRE Guideline Group on Female Fertility Preservation. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020; 2020(4): hoaa052. https://dx.doi.org/10.1093/hropen/hoaa052
  6. Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. Electronic address: jgoldstein@asrm.org. In vitro maturation: a committee opinion. Fertil. Steril. 2021; 115(2): 298-304. https://dx.doi.org/10.1016/j.fertnstert.2020.11.018
  7. Jiang Y., He Y., Pan X., Wang P., Yuan X., Ma B. Advances in oocyte maturation in vivo and in vitro in mammals. Int. J. Mol. Sci. 2023; 24(10): 9059. https://dx.doi.org/10.3390/ijms24109059
  8. Gotschel F., Sonigo C., Becquart C., Sellami I., Mayeur A., Grynberg M. New insights on in vitro maturation of oocytes for fertility preservation. Int. J. Mol. Sci. 2024; 25(19): 10605. https://dx.doi.org/10.3390/ijms251910605
  9. Kedem A., Yerushalmi G.M., Brengauz M., Raanani H., Orvieto R., Hourvitz A. et al. Outcome of immature oocytes collection of 119 cancer patients during ovarian tissue harvesting for fertility preservation. J. Assist. Reprod. Genet. 2018; 35(5): 851-6. https://dx.doi.org/10.1007/s10815-018-1153-1
  10. Sonigo C., Simon C., Boubaya M., Benoit A., Sifer C., Sermondade N. et al. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation? Hum. Reprod. 2016; 31(7): 1493-500. https://dx.doi.org/10.1093/humrep/dew102
  11. Su H.I., Lacchetti C., Letourneau J., Partridge A.H., Qamar R., Quinn G.P. et al. Fertility preservation in people with cancer: ASCO guideline update. J. Clin. Oncol. 2025; 43(12): 1488-515. https://dx.doi.org/10.1200/JCO-24-02782
  12. Anbari F., Khalili M.A., Mahaldashtian M., Ahmadi A., Palmerini M.G. Fertility preservation strategies for cancerous women: an updated review. Turk. J. Obstet. Gynecol. 2022; 19(2): 152-61. https://dx.doi.org/10.4274/tjod.galenos.2022.42272
  13. Лапина И.А., Доброхотова Ю.Э., Сорокин Ю.А., Малахова А.А., Чирвон Т.Г., Таранов В.В., Германович Н.Ю., Ковальская Е.В., Кайкова О.В., Гомзикова В.М., Твердикова М.А. Сохранение репродуктивного материала при помощи метода in vitro maturation у пациенток с онкологическими заболеваниями. Гинекология. 2022; 24(1): 41-6. [Lapina I.A., Dobrokhotova Yu.E., Sorokin Iu.A., Malakhova A.A., Chirvon T.G., Taranov V.V., Germanovich N.Iu., Koval'skaia E.V., Kaikova O.V., Gomzikova V.M., Tverdikova M.A. Preservation of reproductive material using the in vitro maturation method in patients with oncological diseases. Gynecology. 2022; 24(1): 41-6 (in Russian)]. https://dx.doi.org/10.26442/20795696.2022.1.201350

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Oocyte-cumulus complexes obtained by transvaginal puncture of antral follicles in the IVM program. Olympus inverted microscope, x200

Download (234KB)
Indexing metadata
3. Fig. 2. Outcomes of IVM cycles.

Download (229KB)
Indexing metadata

Copyright (c) 2025 Bionika Media